Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
about
Pancreatic cancer: molecular pathogenesis and new therapeutic targets.The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapyRole of glycosyltransferase PomGnT1 in glioblastoma progression.Proteasome inhibitors in cancer therapyActivation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cellsThe 26S proteasome complex: an attractive target for cancer therapyEarly tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice.Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoETS2 and Twist1 promote invasiveness of Helicobacter pylori-infected gastric cancer cells by inducing Siah2Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsNovel therapies for pancreatic cancer: setbacks and progressClinical development of novel proteasome inhibitors for cancer treatment.Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.Monoclonal antibodies in the treatment of pancreatic cancer.Inhibition of the JNK signalling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression.Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stress.New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.Anticancer agent-based marine natural products and related compounds.Nuclear accumulation of seven in absentia homologue-2 supports motility and proliferation of liver cancer cells.Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells.A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.The chemotherapeutic agent bortezomib induces the formation of stress granules.Molecular Targets of Active Anticancer Compounds Derived from Marine Sources.
P2860
Q33899954-89B487EF-859F-40F7-9DD7-8CF97F5CA7CEQ33916030-85E23E8C-3201-4B82-891E-4198A467EA02Q33921377-C5BD19FC-3BB0-4F09-8A50-8CA887673702Q34142223-AFC4DCF9-52C4-4003-A82D-845CC50CD92BQ34596902-3060F169-2CC2-46F3-A36A-8C0061A255F0Q34886810-79688804-3891-42F5-9C83-C2D4665A7F45Q34939959-01B0C7A7-4F02-48AB-84B5-19542745BA61Q35099053-869BF747-043B-4350-9A3C-47CF276C3C6AQ35624079-552807CE-A1D5-44CB-A162-41D99B93AFDBQ36012652-1F5071C2-8A45-4036-8B49-F73A6CC8A525Q36740689-AD131D87-0B60-4F8D-B9B3-6A721D065BE9Q36893244-28F2B851-A39F-49FA-995B-B930F182410FQ36947423-DB139BCC-3B76-4B0B-840F-E88D220905EFQ36955086-695858D1-7A34-46C8-B791-5BA18F71FA13Q37017342-AD3D4E36-2BFF-4059-A19B-A2445668BE20Q37107622-90C92DAB-CFCA-45AF-A11B-613C04CD95F4Q37136598-D6A7ADAF-3055-4680-AB99-09BB880749A5Q37222615-837B0B34-EE1A-4EA7-9406-667B60D5EF86Q37355568-09F5EA62-B4D1-457B-8E9C-574B1ECB343FQ37434495-16B30F47-E778-4E7F-908F-4D4CDE8FE800Q37728340-B55D716F-56A8-456D-8891-71E7EC34C5C5Q38002469-1314DF1D-EE4D-4F24-9787-8FCE4F0F357CQ38218209-DE754CC9-D38D-4CEF-ABF5-CD301DE8DB83Q38258843-9F86657F-73A1-442E-854F-56840C4E8580Q38307526-EB6CA10F-DA9F-4F0C-8DFE-96FD0E053807Q39398502-5F24EC42-E34C-4A13-A698-30DE8C88AD8FQ39752726-FAE4EF71-87AD-400E-92B8-1A300A997545Q39860629-AB0CBA55-F758-419F-BE67-5CA92C5044F7Q40647498-D4DED89B-E302-45E3-9609-9C8CD4191752Q55003938-8CC0A66F-4BE6-4FBD-B474-F0D1BD5C921C
P2860
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Proteasome inhibition activate ...... ys in pancreatic cancer cells.
@en
Proteasome inhibition activates epidermal growth factor receptor
@nl
type
label
Proteasome inhibition activate ...... ys in pancreatic cancer cells.
@en
Proteasome inhibition activates epidermal growth factor receptor
@nl
prefLabel
Proteasome inhibition activate ...... ys in pancreatic cancer cells.
@en
Proteasome inhibition activates epidermal growth factor receptor
@nl
P2093
P2860
P1476
Proteasome inhibition activate ...... ys in pancreatic cancer cells.
@en
P2093
Callum M Sloss
David Ljungman
James C Cusack
Michael A Palladino
Michael Houston
P2860
P304
P356
10.1158/1078-0432.CCR-07-4506
P407
P577
2008-08-01T00:00:00Z